Imran H Iftikhar1, Lana Alghothani2, Alejandro Sardi1, David Berkowitz1, Ali I Musani3. 1. 1 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University School of Medicine, Atlanta, Georgia. 2. 2 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, Ohio; and. 3. 3 Division of Pulmonary, Critical Care, and Sleep Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
RATIONALE: Transbronchial lung cryobiopsy is increasingly being used for the assessment of diffuse parenchymal lung diseases. Several studies have shown larger biopsy samples and higher yields compared with conventional transbronchial biopsies. However, the higher risk of bleeding and other complications has raised concerns for widespread use of this modality. OBJECTIVES: To study the diagnostic accuracy and safety profile of transbronchial lung cryobiopsy and compare with video-assisted thoracoscopic surgery (VATS) by reviewing available evidence from the literature. METHODS: Medline and PubMed were searched from inception until December 2016. Data on diagnostic performance were abstracted by constructing two-by-two contingency tables for each study. Data on a priori selected safety outcomes were collected. Risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool. Random effects meta-analyses were performed to obtain summary estimates of the diagnostic accuracy. RESULTS: The pooled diagnostic yield, pooled sensitivity, and pooled specificity of transbronchial lung cryobiopsy were 83.7% (76.9-88.8%), 87% (85-89%), and 57% (40-73%), respectively. The pooled diagnostic yield, pooled sensitivity, and pooled specificity of VATS were 92.7% (87.6-95.8%), 91.0% (89-92%), and 58% (31-81%), respectively. The incidence of grade 2 (moderate to severe) endobronchial bleeding after transbronchial lung cryobiopsy and of post-procedural pneumothorax was 4.9% (2.2-10.7%) and 9.5% (5.9-14.9%), respectively. CONCLUSIONS: Although the diagnostic test accuracy measures of transbronchial lung cryobiopsy lag behind those of VATS, with an acceptable safety profile and potential cost savings, the former could be considered as an alternative in the evaluation of patients with diffuse parenchymal lung diseases.
RATIONALE: Transbronchial lung cryobiopsy is increasingly being used for the assessment of diffuse parenchymal lung diseases. Several studies have shown larger biopsy samples and higher yields compared with conventional transbronchial biopsies. However, the higher risk of bleeding and other complications has raised concerns for widespread use of this modality. OBJECTIVES: To study the diagnostic accuracy and safety profile of transbronchial lung cryobiopsy and compare with video-assisted thoracoscopic surgery (VATS) by reviewing available evidence from the literature. METHODS: Medline and PubMed were searched from inception until December 2016. Data on diagnostic performance were abstracted by constructing two-by-two contingency tables for each study. Data on a priori selected safety outcomes were collected. Risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool. Random effects meta-analyses were performed to obtain summary estimates of the diagnostic accuracy. RESULTS: The pooled diagnostic yield, pooled sensitivity, and pooled specificity of transbronchial lung cryobiopsy were 83.7% (76.9-88.8%), 87% (85-89%), and 57% (40-73%), respectively. The pooled diagnostic yield, pooled sensitivity, and pooled specificity of VATS were 92.7% (87.6-95.8%), 91.0% (89-92%), and 58% (31-81%), respectively. The incidence of grade 2 (moderate to severe) endobronchial bleeding after transbronchial lung cryobiopsy and of post-procedural pneumothorax was 4.9% (2.2-10.7%) and 9.5% (5.9-14.9%), respectively. CONCLUSIONS: Although the diagnostic test accuracy measures of transbronchial lung cryobiopsy lag behind those of VATS, with an acceptable safety profile and potential cost savings, the former could be considered as an alternative in the evaluation of patients with diffuse parenchymal lung diseases.
Authors: Luis Felipe Flores-Suárez; Marco A Alba; Heidegger Mateos-Toledo; Natllely Ruiz Journal: Curr Rheumatol Rep Date: 2017-09 Impact factor: 4.592
Authors: Robert J Lentz; A Christine Argento; Thomas V Colby; Otis B Rickman; Fabien Maldonado Journal: J Thorac Dis Date: 2017-07 Impact factor: 2.895
Authors: Erin M Wilfong; Robert J Lentz; Adam Guttentag; James J Tolle; Joyce E Johnson; Jonathan A Kropski; Peggy L Kendall; Timothy S Blackwell; Leslie J Crofford Journal: Arthritis Rheumatol Date: 2018-10-27 Impact factor: 10.995
Authors: Sreyankar Nandy; Rebecca A Raphaely; Ashok Muniappan; Angela Shih; Benjamin W Roop; Amita Sharma; Colleen M Keyes; Thomas V Colby; Hugh G Auchincloss; Henning A Gaissert; Michael Lanuti; Christopher R Morse; Harald C Ott; John C Wain; Cameron D Wright; Maria L Garcia-Moliner; Maxwell L Smith; Paul A VanderLaan; Sarita R Berigei; Mari Mino-Kenudson; Nora K Horick; Lloyd L Liang; Diane L Davies; Margit V Szabari; Peter Caravan; Benjamin D Medoff; Andrew M Tager; Melissa J Suter; Lida P Hariri Journal: Am J Respir Crit Care Med Date: 2021-11-15 Impact factor: 21.405